1. Indications and Usage
\nSevere Eosinophilic Asthma:
\nAdd-on maintenance treatment of patients with severe eosinophilic asthma aged 12 years and older.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Subcutaneous Injection ONLY.
\nRecommended Dosage:
\nDose: 30 mg per injection.
\nSchedule:
\nInitial Phase: Once every 4 weeks for the first 3 doses.
\nMaintenance Phase: Once every 8 weeks thereafter.
\nAdministration:
\nMay be administered by a healthcare professional or by the patient (if appropriately trained).
\nInjection sites: Upper arm, thigh, or abdomen.
\n3. Mechanism of Action
\nTarget:
\nBinds with high affinity to the alpha subunit of the human interleukin-5 receptor (IL-5R\u03b1) expressed on the surface of eosinophils and basophils.
\nDual Mechanism (Blocking + Killing):
\nSignaling Blockade: Blocks the binding of IL-5 to its receptor, inhibiting eosinophil proliferation and survival.
\nAntibody-Dependent Cell-Mediated Cytotoxicity (ADCC): Through its Fc domain, it recruits Natural Killer (NK) cells to induce apoptosis (programmed cell death) of eosinophils.
\nResult:
\nRapid and near-complete depletion of eosinophils in the blood and airway tissues.
\n4. Safety and Warnings
\nDo Not Discontinue Asthma Medicines:
\nDo not discontinue systemic or inhaled corticosteroids when initiating Benralizumab.
\nNot for Acute Attacks:
\nNot indicated for the relief of acute bronchospasm, acute exacerbations of asthma, or status asthmaticus.
\nHypersensitivity Reactions:
\nHypersensitivity reactions (e.g., anaphylaxis, angioedema, rash, urticaria) have been reported.
\nParasitic Infections:
\nEosinophils play a role in immune defense against parasites. Monitor patients for potential parasitic (helminth) infections.
\nVaccinations:
\nPatients should be up to date with all vaccinations prior to initiating therapy. Avoid live vaccines during treatment.
\n5.Adverse Reactions
\nMost Common:
\nHeadache, pharyngitis, fatigue, injection site reactions (e.g., erythema, pain), and fever.
\n6.Drug Interactions
\nNo Clinical Significance:
\nAs a protein (monoclonal antibody), it is not metabolized by cytochrome P450 enzymes. No clinically significant drug interactions have been identified.
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Benralizumab.
\nAppearance: Clear to slightly opalescent, colorless to pale yellow solution.
\nDelivery System: Available as a single-dose prefilled syringe or a single-dose autoinjector.
\nStorage: Store in a refrigerator at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). Do not freeze or shake.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u51e1\u8212\u5353 \u00ae(Fasenra\u00ae)
\nGeneric Name: Benralizumab
\nStrength: 30 mg (1.0 mL) per pre-filled pen, 1 pen per box
\nManufacturer: AstraZeneca AB (Sweden)
\nMarketing Authorization Holder: AstraZeneca AB
\nDomestic Responsible Entity: AstraZeneca Investment (China) Co., Ltd.
\nApproval Date in China: August 13, 2024
\nRegistration Number:\u56fd\u836f\u51c6\u5b57 SJ20240040
\nStorage: Store refrigerated at 2\u00b0C\u20138\u00b0C, do not freeze. Keep away from direct light. Once removed from refrigeration, may be stored below 25\u00b0C for up to 14 days and must be used within this period. Refer to the full package insert for detailed storage requirements.<\/p>\n
Price&Cost:Contact Us now for the best price of Benralizumab\uff08Fasenra\uff09<\/p>\n","protected":false},"featured_media":4169,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[75],"product_cat":[25],"product_tag":[],"class_list":["post-4168","product","type-product","status-publish","has-post-thumbnail","product_brand-astrazeneca","product_cat-injection","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n